Clinical trials: CORE Condition
Covid19
COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
This is a phase 1/2 study in adult healthy subjects that have previously been vaccinated with an FDA-authorized vaccine against COVID-19.
- Trial name
- NCT04845191
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Angina Pectoris, Angina, Unstable
Intravascular Near Infrared Spectroscopy (NIRS) Bifurcation - Lipid Core Plaque Shift Study
This pilot study is going to examine the hypothesis that in coronary arteries, soft lesions that contain lipid cores, but are not calcified or fibrotic and are located in proximity to side branches, are associated with side…
- Conditions
- Angina Pectoris, Angina, Unstable, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00905671
- Testing
- LipiScan Coronary Imaging Catheter
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Infraredx
Histologically-proven and Radiologically-confirmed Solid Tumors
An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function
This study is designed to obtain pharmacokinetic data following a single-dose 20-minute i.v. administration of ASA404 (900, 1200, or 1800 mg/m2) in adult cancer patients with varying degrees of hepatic impairment.
- Trial name
- NCT01278849
- Testing
- ASA404
- Where
- 4 sites in Italy, New Zealand
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Body Temperature, Febrile
Clinical Accuracy Validation of the Moni-Patch Temperature Monitoring Patch System
Moni-Patch Temperature Monitoring Patch System, a non-invasive, continuous temperature monitoring device designed to estimate core body temperature by applying a Sensor to the neck.
- Trial name
- NCT07397078
- Testing
- Moni-Patch Temperature Monitoring Patch System
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Murata Vios, Inc.
Heart Failure, Congestive, Heart Decompensation
Registry for Acute Decompensated Heart Failure Patients
The purpose of the ADHERE study is to develop a multi-center, observational, open-label registry of the management strategies of patients treated in the hospital for acute Heart Failure in the United States.
- Trial name
- NCT00366639
- Testing
- Acute Decompensated Heart Failure
- Volunteers
- 24,118 people
- Sponsor
- Scios, Inc.
Juvenile Idiopathic Arthritis
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
This long-term, open-label extension study will evaluate the safety of RoActemra/Actemra (tocilizumab) in patients with polyarticular-course juvenile idiopathic arthritis who completed the WA19977 core study.
- Trial name
- NCT01667471
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Hoffmann-La Roche
Coronary Artery Disease
Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study
The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native coronary arteries with a reference vessel diameter of…
- Trial name
- NCT02419521
- Testing
- Resolute Onyx Stent - 2.25 mm - 4.0 mm
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Medtronic Vascular
Autism Spectrum Disorder, Autism
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
This study will investigate the efficacy, safety and tolerability of L1-79 in participants aged 12-21 years who have been diagnosed with ASD with a score of >/= 70 on the Wechsler Abbreviated Scale of Intelligence (WASI-II), and…
- Trial name
- NCT05067582
- Testing
- L1-79
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Yamo Pharmaceuticals LLC
Chronic Hepatitis B
A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B
This primary objectives of this study are to compare the efficacy, safety, and tolerability of tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) for the treatment of pre-core mutant chronic hepatitis B.
- Trial name
- NCT00117676
- Testing
- TDF, ADV, FTC/TDF
- Where
- 80 sites in United States, Australia and 13 more
- Volunteers
- 382 people
- Sponsor
- Gilead Sciences
Hepatitis C, Dried Blood Spot
Evaluation of Hepatitis C Viral Load Quantification on DBS in Vietnam
In Vietnam, the prevalence of hepatitis C virus (HCV) infection is estimated between 0.4% and 5%, which is much higher than the prevalence in Europe or in the USA.
- Trial name
- MOVIDA-Hep (NCT03670251)
- Testing
- Blood sampling
- Where
- 2 sites in Vietnam
- Volunteers
- 315 people
- Sponsor
- Institut Pasteur
Transfusional Iron Overload, β-thalassemia Major
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
In this 4-year extension study the safety, efficacy and and pharmacokinetics of deferasirox in regularly transfused pediatric patients with β-thalassemia major was assessed.
- Conditions
- Transfusional Iron Overload, β-thalassemia Major, Pediatric Rare Anemia
- Trial name
- NCT00390858
- Testing
- Deferasirox
- Where
- 4 sites in France, Italy
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Gout
A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)
The 24-week, dose-ranging, multi-center, double-blind, double-dummy, active-controlled core study investigated the prophylactic effect of canakinumab on the signs and symptoms of acute flares in chronic gout patients initiating…
- Trial name
- NCT00819585
- Testing
- Canakinumab, Colchicine, Allopurinol
- Where
- 89 sites in United States, Argentina and 16 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection
The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.
- Trial name
- NCT00124215
- Testing
- GI-5005
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- GlobeImmune
Metastatic Cancer With Impaired Renal Function, Metastatic Cancer With Normal Renal Function
An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404
The purpose of this study is to determine the effect of the ASA404 infusion rate and co-administrating ASA404 with paclitaxel + carbopaltin chemotherapy regimen or docetaxel on the pharamcokinetics (PK) of free and total ASA404.
- Trial name
- NCT01240642
- Testing
- ASA404
- Where
- 4 sites in Belgium
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Paget's Disease of the Bone
Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and…
- Trial name
- NCT00740129
- Testing
- Zoledronic Acid
- Where
- 11 sites in Belgium, Canada and 4 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
The extension study followed the core study CAMN107ECN02 (NCT01275196). which is an open-label, two armed study. All patients enrolled in this extension study were able to benefit from the treatment given in CAMN107ECN02 per…
- Trial name
- NCT02272777
- Testing
- Imatinib, Nilotinib
- Where
- 12 sites in China
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Fever
Fever Algorithm Development of a Non-invasive Wearable Core Body Temperature Sensor System in Intensive Care Unit Patients
Background and Rationale: The gold standard to assess fever, is to conduct invasive intravascular, esophageal or bladder thermistor core body temperature (CBT) measurements.
- Trial name
- NCT04182945
- Testing
- Data collection for algorithm development
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- greenTEG AG
NSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)
The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.
- Trial name
- ELEPHAS-01 (NCT05478538)
- Testing
- Core Needle, Forceps, or Punch Biopsy
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- Elephas
Type 2 Diabetes Mellitus, Cardiovascular Disease
Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases)
The purpose of this study was to determine whether, in patients with type 2 diabetes and pre-existing disease of the heart and the circulatory system and/or the kidney, aliskiren at a target dose of 300 mg once daily (compared to…
- Trial name
- ALTITUDE (NCT00549757)
- Testing
- Aliskiren
- Where
- 776 sites in United States, Argentina and 35 more
- Volunteers
- 8,606 people
- Sponsor
- Novartis Pharmaceuticals
SARS-CoV-2 Infection
A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins
PRIME-2-CoV_Beta is the first clinical candidate based on the attenuated 2nd generation Orf virus (ORFV) vaccine platform which encodes for the structural spike (S)- and nucleocapsid (N) protein of SARS-CoV-2.
- Trial name
- NCT05367843
- Testing
- PRIME-2-CoV_Beta
- Where
- 7 sites in United States, Germany
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Speransa Therapeutics